Close

Mallinckrodt (MNK) to Initiate Company-Sponsored Clinical Trial of Acthar in ALS; FDA Grants Fast Track Status

Go back to Mallinckrodt (MNK) to Initiate Company-Sponsored Clinical Trial of Acthar in ALS; FDA Grants Fast Track Status

Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS)

November 21, 2016 7:00 AM EST

CHESTERFIELD, United Kingdom, Nov. 21, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed that it will initiate a company-sponsored, Phase 2 proof-of-concept clinical trial to assess the efficacy of H.P. Acthar® Gel (repository corticotropin injection) in patients with Amyotropic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease). The study is expected to begin in the first half of... More